Abstract: An isolated and purified enzyme exhibiting protease activity at a pH of 4-7 which exhibits protease in 5% hydrogen peroxide and which is encoded by a DNA sequence which hybridizes to a DNA sequence depicted in SEQ ID NO: 1 or 2. Methods are described for using the protease compositions in reducing vescosity, cleaning contact lenses, baking, and preparing animal feed.
Type:
Grant
Filed:
September 29, 1999
Date of Patent:
February 20, 2001
Inventors:
Henrik Dalbøge, Stephan Christgau, Lene Nonboe Andersen, Lene Venke Kofod, Markus Sakari Kauppinen, Jack Bech Nielsen, Claus Dambmann
Abstract: There is provided a method or system that utilizes fluorescence in a sample that would otherwise yield inaccurate results due to spectrally interfering components. The system quantifies spectral interference of a fluorescent label.
Abstract: An enzyme exhibiting xylanase activity, which enzyme is immunologically reactive with antibody raised against a purified xylanase derived from Aspergillus aculeatus, CBS 101.43. The enzyme may be used for degrading plant cell wall components, e.g., in the preparation of feed, in baking, in the paper and pulp industry, and in connection with separation of wheat into starch and gluten.
Type:
Grant
Filed:
July 16, 1998
Date of Patent:
June 27, 2000
Assignee:
Novo Nordisk A/S
Inventors:
Lene Venke Kofod, Markus Sakari Kauppinen, Stephan Christgau, Hans Peter Heldt-Hansen, Henrik Dalb.o slashed.ge, Lene Nonboe Andersen, Joan Qi Si, Tina Sejersg.ang.rd Jacobsen, Niels Munk, Anette Mullertz
Abstract: A pharmaceutical formulation comprising a growth hormone pretreated with zinc and optionally lysine or calcium ions shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.
Type:
Grant
Filed:
July 23, 1998
Date of Patent:
February 8, 2000
Assignee:
Novo Nordisk A/S
Inventors:
Hans Holmegaard S.o slashed.rensen, Ole Hvilsted Olsen, Lars Thim, Christensen Thorkild, Per Balschmidt
Abstract: An isolated and purified enzyme exhibiting protease activity at a pH of 4-7 which exhibits protease activity in 5% hydrogen peroxide and which is encoded by a DNA sequence which hybridizes to a DNA sequence depicted in SEQ ID NO. 1 or 2.
Type:
Grant
Filed:
November 12, 1998
Date of Patent:
December 7, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Henrik Dalb.o slashed.ge, Stephan Christgau, Lene Nonboe Andersen, Lene Venke Kofod, Markus Sakari Kauppinen, Jack Bech Nielsen, Claus Dambmann
Abstract: A pharmaceutical preparation comprising a growth hormone and asparagine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature.
Abstract: Methods of dyeing a material, comprising treating the material with a dyeing system which comprises (a) one or more mono-, di- or polycyclic aromatic or heteroaromatic compounds, and (b) (i) a hydrogen peroxide source and an enzyme exhibiting peroxidase activity or (ii) an enzyme exhibiting oxidase activity on the one or more aromatic or heteroaromatic compounds; wherein the material is a fabric, yarn, fiber, garment or film made of cotton, diacetate, flax, linen, lyocel, polyacrylic, synthetic polyamide, polyester, ramie, rayon, tencel, or triacetate.
Type:
Grant
Filed:
December 19, 1996
Date of Patent:
October 26, 1999
Assignees:
Novo Nordisk A/S, Novo Nordisk Bio-Chem North America
Abstract: The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions.
Abstract: The present invention relates to therapeutically active compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.
Type:
Grant
Filed:
October 27, 1997
Date of Patent:
July 6, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Poul Jacobsen, Svend Treppendahl, Paul Stanley Bury, Anders Kanstrup, Lise Brown Christiansen
Abstract: The invention is directed to agents used in the retention of color values on fabrics formed from cellulose fibers (color clarification agents) and to a method for treatment of such fabrics. The method comprises treating a colored fabric with a cellulase and a polymer selected from the group consisting of a polyalkylene oxide graft polymer, a polyamino acid polymer, and a carboxylated polysaccharide polymer in an amount effective to preserve the color of the fabric after at least one wash cycle.
Type:
Grant
Filed:
October 18, 1996
Date of Patent:
July 6, 1999
Assignees:
Novo Nordisk A/S, Novo Nordisk Biochem North America, Inc.
Inventors:
Sonja I. Salmon, Anita R. Mishra, Jack B. Nielsen
Abstract: The present invention provides novel uses of compounds of general formula I ##STR1## wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R2 and R3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiologic gynaecomastia.
Type:
Grant
Filed:
March 4, 1997
Date of Patent:
July 6, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Niels Korsgaard, Michael Shalmi, Birgitte Hjort Guldhammer
Abstract: The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions.
Abstract: An enzyme exhibiting xylanase activity, which enzyme is immunologically reactive with an antibody raised against a purified xylanase derived from Aspergillus aculeatus, CBS 101.43. The enzyme may be used for degrading plant cell wall components e.g. in the preparation of feed, in baking, in the paper and pulp industry and in connection with separation of wheat into starch and gluten.
Type:
Grant
Filed:
July 30, 1997
Date of Patent:
March 23, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Lene Venke Kofod, Markus Sakari Kauppinen, Stephan Christgau, Hans Peter Heldt-Hansen, Henrik Dalb.o slashed.ge, Lene Nonboe Andersen, Joan Qi Si, Tina Sejersg.ang.rd Jacobsen, Niels Munk, Anette Mullertz
Abstract: This invention relates to a directly compressible enzyme powder produced by mixing a liquid enzyme preparation with a suitable carrier, using the principle of wet granulation, whereby the step of freeze drying and spray-drying is avoided. The resulting enzyme powder has extraordinary good compression qualities and may directly be tabletted.
Abstract: The present invention provides novel uses of compounds of general formula I ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R.sup.2 and R.sup.3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis.
Type:
Grant
Filed:
August 18, 1997
Date of Patent:
March 23, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Niels Korsgaard, Michael Shalmi, Jan Ulrik Weis, Birgitte Hjort Guldhammer
Abstract: A method for treating an aqueous protein solution so as to kill microorganisms which may be present therein, but without causing coagulation, comprises either (1) mixing the solution with sufficient enzymatically produced protein hydrolysate (H1) to prevent coagulation of the mixture when the mixture is subsequently subjected to a heat treatment to kill microorganisms, and then subjecting the mixture to such a heat treatment, or (2) using one or more enzymes to hydrolyze protein in the aqueous protein solution to an extent sufficient to prevent coagulation of the resulting liquid hydrolysate (H2) when it is subsequently subjected to a heat treatment to kill microorganisms, and then subjecting the liquid hydrolysate (H2) to such a heat treatment. The use of aqueous protein solutions treated in this manner in the production of a foodstuff, such as a meat-based foodstuff, contributes very significantly to reducing any risk of contamination of the foodstuff by harmful microorganisms.
Abstract: The present invention relates to hydroxy alkyl piperidine compounds and pharmaceutical compositions thereof which can be used to treat diabetes.
Abstract: The invention relates to a novel substance with activity against insect pests of the order Diptera. The invention further relates to the substance which acts together with a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties. The invention further relates to a novel strain(s) of Bacillus thuringiensis which produces such a substance. The invention further relates to pesticidal compositions comprising the substance and a pesticidal carrier, or the substance and a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties as well as methods of using the pesticidal compositions to control a pest.
Type:
Grant
Filed:
July 11, 1994
Date of Patent:
January 12, 1999
Assignee:
Abbott Laboratories
Inventors:
Chi-Li Liu, William D. Lidster, Carmen Sanchez Lopez
Abstract: An .alpha.-amylase characterized by having a specific activity at least 25% higher than the specific activity of Termamyl.RTM. at a temperature in the range of 25.degree. C. to 55.degree. C. and at a pH value in the range of pH 8 to pH 10.
Type:
Grant
Filed:
May 22, 1997
Date of Patent:
January 5, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Helle Outtrup, Henrik Bisg.ang.rd-Frantzen, Peter Rahbek stergaard, Michael Dolberg Rasmussen, Pia Van Der Zee